News | November 05, 2021
UK authorises first Covid-19 pill
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Expertise in exosomes isolation and characterization will drive innovation in this field
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Filing marks first protein-based vaccine submitted to MHRA for authorization
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
